



26th Nordic-Baltic Congress of Cardiology 2017

Congress Speaker, 2017



MARIUS MIGLINAS, M.D., Ph.D

Lead to Nephrology Center at the Vilnius University hospital, Vilnius University in Vilnius, Lithuania

Dr. Miglinas currently serves as a President Lithuanian Kidney Foundation and as a President of Lithuanian Hypertension Society. He also takes a lead to Nephrology Center at the Vilnius University hospital, Vilnius University in Vilnius (Lithuania).

Dr. Miglinas received his medical degree from Vilnius University in Lithuania. He trained as an intern in Vilnius, and as an International Society of Nephrology Fellow at Glasgow University Western Infirmary in Scotland, U.K.

Dr. Miglinas received the award of Matsumae International Foundation (Japan) to study uremic toxicity in chronic renal failure patients at the Nagoya University, Nagoya, Japan under guidance of prof. T.Niwa in 2002. In 2007 he has been trained as an EDTA/ERA Fellow in Vienna university hospital (Austria) in the field of the kidney recipient waiting list management, approach to the sensitized kidney recipients and peritoneal dialysis programme set up. Dr. Miglinas has also been trained at the Transplant and Renal Education Center, Westmead hospital, Sydney (Australia) in both kidney and kidney-pancreas transplantation under guidance of prof. J. Chapman from February to April, 2013.

Dr. Miglinas' research interests are renal biopsy and glomerular involvement in primary glomerular diseases, kidney involvement in diabetes, thrombotic microangiopathies and arterial hypertension, management of resistant hypertension and hypertension in renal patients and diabetics, kidney transplantation, interventional nephrology and chronic kidney disease epidemiology.

His expertise includes both a solid theoretical background and strong clinical skills in such fields as glomerular and diabetic kidney disease management, treatment of hypertension in chronic kidney disease and resistant hypertension work-up, hemodialysis/peritoneal dialysis-related complications, immunologic problems (ABO incompatibility, positive XM) in kidney transplantation, kidney-pancreas transplantation issues, and kidney transplant recipients' long-term management.

Dr. Miglinas is frequently invited to speak throughout Lithuania, Baltic states and abroad.

Important publications:

1. Psoriasis in a patient on peritoneal dialysis: a two-sided mirror. Iran J Kidney Dis. 2017;11(1):70-73
2. Nephrology crossword: transplantation in a box. Kidney Int 2017; 91(1): 257-258.
3. Mesenchymal stem cell use in renal transplantation: a review. Jokull Journal 2016; 66(9): 44-55.
4. Malnutrition assessment in hemodialysis patients: role of bioelectrical



26th Nordic-Baltic Congress of Cardiology 2017

- impedance analysis phase angle. *J Ren Nutr* 2016; 26(6): 391-395. doi: 10.1053/j.jrn.2016.05.004.
5. Successful adsorption of anti-A/B antibodies with multiple personal use columns in ABO incompatible kidney recipients: A single centre experience. *J Clin Apher* 2016; 22. doi: 10.1002/jca.21481.
 6. Tumour-induced osteomalacia: a literature review and a case report. *World J Surg Oncol*. 2016;14(1):4. doi: 10.1186/s12957-015-0763-7.
 7. Impact of renal sympathetic denervation on cardiac sympathetic nerve activity evaluated by cardiac MIBG imaging. *EuroIntervention*. 2016;11(9):1070-1076. doi: 10.4244/EIJV11I9A215.
 8. Nationwide renal biopsy data in Lithuania 1994 - 2012. *Int Urol Nephrol* 2015; 47(4): 655-662.
 9. Clinical approach to noninvasive and invasive blood pressure monitoring in end-stage renal disease patients on dialysis. *Blood Press Monit* 2014; 19(6): 370.
 10. Utility of renal biopsy in the clinical management of renal disease: hematuria should not be missed. *Kidney Int* 2014; 86(6): 1269.
 11. Malignancy after renal transplantation: a single-center experience. *Ann Transplant* 2014; 19: 456-463.
 12. A perspective from the Baltics regarding the Canadian Society of Nephrology commentary on the KDIGO Glomerulonephritis Guideline. *Am J Kidney Dis* 2014; 64(2): 315.
 13. Proteinuria after kidney transplantation. *J Nephrol Ther*, 2013; 4(145): 2161-0959.
 14. Delayed graft function: risk factors and the effects of early function and graft survival. *Transplant Proc*. 2013 May;45(4):1363-7.
 15. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012 Dec 6;367(23):2204-13.
 16. Incompatible blood groups in kidney transplantation – achievements and challenges. *Theory and Practice in Medicine*. 2012, vol. 18, no. 4.2. ISSN 1392-1312 p. 564-570
 17. Kidney transplantation in Lithuania: more than 40 years of experience. *Theory and Practice in Medicine* . 2012, vol. 18, no. 4.2. ISSN 1392-1312 p. 592-596
 18. Effect of salt consumption on arterial stiffness. *Theory and Practice in Medicine*. 2012, vol. 18, no. 4.2. ISSN 1392-1312 p. 558-563
 19. Exercise for the dialysis and chronic renal failure patients. *Theory and Practice in Medicine* .2012, vol. 18, no. 4.2. ISSN 1392-1312 p. 582-587
 20. Resistant hypertension: demographic information, clinical characteristics, treatment. *Theory and Practice in Medicine* . 2012, vol. 18, no. 4.2. ISSN 1392-
 21. Primary hyperaldosteronism: hypertensive patients are underinvestigated. *Cardiology* 2009; 113 (Suppl 1): 100-101
 22. The epidemiology of end-stage renal disease in the Baltic countries: an evolving picture. *Nephrol Dial Transplant* 2001; 16: 1338 – 1342
 23. Treatment of hyperlipidemia in the nephrotic syndrome: The effects of atorvastatin therapy. *Atherosclerosis* 2000; 151(1): 304
 24. Workshop on molecular biology for the nephrologist. *Nephrol Dial Transplant* 1999; 14(12): 2963